Cite
MLA Citation
Jordana E Hoppe et al.. “Long-term safety of lumacaftor–ivacaftor in children aged 2–5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.” Lancet, vol. 9, no. 9, 2021, pp. 977–988. http://access.bl.uk/ark:/81055/vdc_100144251782.0x00000c